title: Corneal infiltrates after corneal collagen cross-linking.
abstract: OBJECTIVE
  To present a case of advancing keratoconus treated with corneal collagen cross-linking (CXL) with ultraviolet A (UVA) light and riboflavin complicated with sterile infiltrates.
  
  
  METHODS
  The patient's cornea was de-epithelialized and CXL was performed with application of riboflavin and exposure to UVA light (370 nm, 3 mW/cm2) for 30 minutes.
  
  
  RESULTS
  Early in the postoperative period, the patient presented with 11 deep stromal infiltrates of 1 to 2 mm with clear demarked edges in a circle near the limbus with some clear cornea. Corneal cultures were negative. Treatment consisted of antibiotic ofloxacin and tobramycin four times daily, and dexamethasone drops six times daily. After 2 months, scars remained evident.
  
  
  CONCLUSIONS
  This complication has not been reported previously and may be an individual hypersensitivity reaction to the riboflavin or UVA light in the anterior stroma.
authors.affiliation: Aristotle University of Thessaloniki and A' University Eye-Clinic, AHEPA Hospital, Thessaloniki, Greece.
authors.forename: George F
authors.initials: GF
authors.lastname: Mangioris
authors.forename: Domniki N
authors.initials: DN
authors.lastname: Papadopoulou
authors.forename: Miltiadis O
authors.initials: MO
authors.lastname: Balidis
authors.forename: Jordan L
authors.initials: JL
authors.lastname: Poulas
authors.forename: Nikolaos Th
authors.initials: NT
authors.lastname: Papadopoulos
authors.forename: Theo
authors.initials: T
authors.lastname: Seiler
mesh_terms: D000328:Adult; D003094:Collagen / Q000378:metabolism*; D003316:Corneal Diseases / Q000139:chemically induced* / Q000175:diagnosis / Q000188:drug therapy; D003319:Corneal Stroma / Q000378:metabolism*; D003432:Cross-Linking Reagents / Q000009:adverse effects*; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D007640:Keratoconus / Q000188:drug therapy / Q000378:metabolism; D015242:Ofloxacin / Q000627:therapeutic use; D017319:Photosensitizing Agents / Q000009:adverse effects; D011183:Postoperative Complications; D012256:Riboflavin / Q000009:adverse effects; D014031:Tobramycin / Q000627:therapeutic use; D014466:Ultraviolet Rays
chemical_list: D003432:Cross-Linking Reagents; D017319:Photosensitizing Agents; D003094:Collagen; D015242:Ofloxacin; D012256:Riboflavin; D014031:Tobramycin